Informace o publikaci

Intracerebellar application of P19-derived neuroprogenitor and naive stem cells to Lurcher mutant and wild type B6CBA mice

Autoři	HOUDEK Zbynek CENDELIN Jan KULDA Vlastimil BABUSKA Vaclav CEDIKOVA Miroslava KRALICKOVA Milena PACHERNÍK Jiří STEFANO George B VOZEH Frantisek
Rok publikování	2012
Druh	Článek v odborném periodiku
Časopis / Zdroj	Medical Science Monitor (International Medical Journal of Experimental and Clinical Research)
Fakulta / Pracoviště MU	Přírodovědecká fakulta
Citace
www	Full Text
Doi	http://dx.doi.org/10.12659/MSM.882726
Klíčová slova	carcinoma stem cells; cerebellum; Lurcher; neuroprogenitor cells; neurotransplantation
Popis	Background: Neurotransplantation has great potential for future treatments of various neurodegenerative disorders. Preclinically, the Lurcher mutant mouse represents an appropriate model of genetically-determined olivocerebellar degeneration. The aim of the present study was to assess survival of naive and neurally differentiated P19 carcinoma stem cells following transplantation into the cerebellum of Lurcher mice and wild type littermates. Material/Methods: Adult normal wild type (n=51) and Lurcher mutant mice (n=87) of the B6CBA strain were used. The mean age of the animals at the time of transplantation was 261.5 days. Suspension of naive and neurally differentiated P19 carcinoma stem cells was injected into the cerebellum of the mice. In the Lurcher mutants, 2 depths of graft injection were used. Three weeks after implantation the brains of experimental animals were examined histologically. Results: Survival of neuroprogenitor grafts at a depth of 1.6 mm was significantly higher in wild type vs. Lurcher mutant mice. In wild type mice, the typical graft localization was in the middle of the cerebellum, whereas in Lurcher mice the graft was never found inside the degenerated cerebellum and was primarily localized in the mesencephalon. Conclusions: We conclude that the appearance and low survival rate of cerebellar P19 carcinoma stem cell grafts in the Lurcher mutant mice weigh against the therapeutic value of this cell line in preclinical studies of neurodegeneration.